KLI

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Metadata Downloads
Abstract
There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the efficacy of capecitabine and bevacizumab. This single-center retrospective study included 157 patients between May 2011 and February 2018, who received bevacizumab plus capecitabine as later-line chemotherapy after progressing with irinotecan, oxaliplatin, and fluoropyrimidines. The study treatment consisted of bevacizumab 7.5?mg/kg on day 1 and capecitabine 1,250?mg/m
Author(s)
김규표김선영김정은김태원방영학이지성홍용상
Issued Date
2021
Type
Article
Keyword
BevacizumabCancer therapyChemotherapyColorectal cancerColorectal carcinomaCytotoxicityDisease controlGastrointestinal cancerIrinotecanMetastasesMetastasisOxaliplatinPatientsSurvival
DOI
10.1038/s41598-021-86482-x
URI
https://oak.ulsan.ac.kr/handle/2021.oak/7861
https://ulsan-primo.hosted.exlibrisgroup.com/primo-explore/fulldisplay?docid=TN_cdi_doaj_primary_oai_doaj_org_article_90406605d8d147a48bfed13fe0d89c7a&context=PC&vid=ULSAN&lang=ko_KR&search_scope=default_scope&adaptor=primo_central_multiple_fe&tab=default_tab&query=any,contains,Bevacizumab%20plus%20capecitabine%20as%20later-line%20treatment%20for%20patients%20with%20metastatic%20colorectal%20cancer%20refractory%20to%20irinotecan,%20oxaliplatin,%20and%20fluoropyrimidines&offset=0&pcAvailability=true
Publisher
SCIENTIFIC REPORTS
Location
영국
Language
영어
ISSN
2045-2322
Citation Volume
11
Citation Number
1
Citation Start Page
0
Citation End Page
0
Appears in Collections:
Medicine > Medicine
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.